Streetbeat News

Products Services

LASE

Laser Photonics has received an order from Electrostatic Refinishing Solutions for its CleanTech Laser Cleaning System. The system is used for surface preparation, paint removal, and surface cleaning.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 11:11 am

BFLY

Butterfly Network, Inc. (NYSE:BFLY) has announced the addition of two new ultrasound education offerings, Butterfly Certified™ and ScanLab™, to its suite of education products. Butterfly Certified™ is a set of virtual and in-person POCUS courses, delivered in partnership with the Global Ultrasound Institute. ScanLab™ is an AI-powered educational application for ultrasound scanning practice.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 11:08 am

META

TikTok and Instagram, owned by ByteDance and Meta Platforms Inc. (NASDAQ:META) respectively, continue to dominate as the world's most downloaded apps in September. Elon Musk's X and Mark Zuckerberg's Threads were notably absent from the rankings. X has seen a significant 18% drop in app downloads compared to last year, and its fortunes have plummeted to an alarming low, attracting only 10 million users between August and September.

Portfolio Pulse from Ananya Gairola

October 10, 2023 | 11:07 am

NVS

OLMA

Olema Oncology has expanded its collaboration agreement with Novartis, significantly increasing the size of the ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 11:06 am

PSTV

Plus Therapeutics, Inc. (PSTV) has completed dosing in Cohort 4 of the ReSPECT-LM Phase 1/2a clinical trial of rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases from solid tumors. The company has also completed the transfer of proprietary materials, protocols, and equipment from Biocept under the terms of the recently announced expanded agreement for CNSide.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 11:04 am

AKRO

Akero Therapeutics, Inc. (NASDAQ:AKRO) reported a 36-week analysis of its 96-week Phase 2b SYMMETRY study. The study evaluates the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH). The results showed a trend on fibrosis improvement and statistically significant results for NASH resolution, markers of liver injury and fibrosis, insulin sensitization and lip.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 11:03 am

BTAI

BioXcel Therapeutics has announced overall survival data from its Phase 2 trial of BXCL701 plus Keytruda in patients with small cell neuroendocrine prostate cancer. The data shows a median overall survival of 13.6 months and a 12-month survival rate of 56.5%.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 11:03 am

OCGN

The National Institute of Allergy and Infectious Diseases will conduct a trial comparing the administration of Ocugen's mucosal vaccine candidate, OCU500, via inhalation into the lungs and as nasal spray. The clinical trials are scheduled to start in early 2024. Ocugen is developing this novel anti-viral mucosal vaccine platform initially targeting COVID-19 and influenza.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 10:38 am

CNTG

Centogene N.V. (NASDAQ:CNTG) has expanded its multiomic diagnostic portfolio, MOx, to include transcriptomic analysis. The updated MOx 2.0 combines DNA sequencing, biochemical testing, and RNA sequencing to provide a comprehensive testing capability. Transcriptomics can reveal mutation-specific RNA patterns, differences in gene expression, and responses to environmental or physiological changes.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 10:34 am

MRK

Merck's Phase 3 KEYNOTE-671 trial of Keytruda, a perioperative treatment regimen for resectable stage II, IIIa or IIIb non-small cell lung cancer, has met its dual primary endpoint of overall survival.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 10:34 am